Accès gratuit
Numéro
Méd. Intensive Réa.
Volume 26, Numéro 3, Mai 2017
Infectieux
Page(s) 167 - 176
Section Mise au point / Update
DOI https://doi.org/10.1007/s13546-017-1265-4
Publié en ligne 17 février 2017
  • Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN, (1996) Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275: 134–141 [CrossRef] [PubMed] [Google Scholar]
  • Hussein AS, Shafran SD, (2000) Acute bacterial meningitis in adults. A 12-year review. Medicine (Baltimore) 79: 360–368 [PubMed] [Google Scholar]
  • Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF, (1996) The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 174: 986–993 [CrossRef] [PubMed] [Google Scholar]
  • Centre national de référence des pneumocoques. Rapport d’activité 2002–épidémiologie 2001. http://cnr-pneumo.com [Google Scholar]
  • 2000) Révision de la IVe Conférence de consensus en thérapeutique anti-infectieuse de la Société de pathologie infectieuse de langue française (SPILF). Med Mal Infect 30: 566–580 [Google Scholar]
  • Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL; American Thoracic Society, (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163: 1730–1754 [CrossRef] [PubMed] [Google Scholar]
  • 1996) Les méningites purulentes communautaires. 9e Conférence de consensus en thérapeutique anti-infectieuse. Med Mal Infect 26: 1–8 [Google Scholar]
  • Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ, (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39: 1267–1284 [CrossRef] [PubMed] [Google Scholar]
  • Cnr-pneumo.com/rapport d’activité 2015–épidémiologie 2014. Accédé le 09/11/2016 [Google Scholar]
  • http://www.sfmmicrobiologie.org/UserFiles/files/casfm/CASFM_EUCAST_V1_2016.pdf. Accédé le 04/01/2017 [Google Scholar]
  • World Health Organisation, (2012) Wkly Epidemiol Rec 87: 129–144 [PubMed] [Google Scholar]
  • 2009) XVIIe Conférence de consensus en thérapeutique anti-infectieuse. Prise en charge des méningites bactériennes aiguës communautaires (à l’exclusion du nouveau-né). Med Mal Infect 39: 175–186 [PubMed] [Google Scholar]
  • 2006) XVe Conférence de consensus en thérapeutique anti-infectieuse. Prise en charge des infections des voies respiratoires basses de l’adulte immunocompétent. Med Mal Infect 36: 235–244 [PubMed] [Google Scholar]
  • Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TMJr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society, (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44: S27–S72 [CrossRef] [PubMed] [Google Scholar]
  • Waterer GW, Somes GW, Wunderink RG, (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161: 1837–1842 [CrossRef] [PubMed] [Google Scholar]
  • Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, Chedid MB, Hui DS; Andremont A, Chiou CC; International Pneumococcal Study Group, (2004) Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170: 440–444 [CrossRef] [PubMed] [Google Scholar]
  • Olive D, Georges H, Devos P, Boussekey N, Chiche A, Meybeck A, Alfandari S, Leroy O, (2011) Severe pneumococcal pneumonia: impact of new quinolones on prognosis. BMC Infect Dis 11: 66 [CrossRef] [PubMed] [Google Scholar]
  • Meijvis SC, van de Garde EM, Rijkers GT, Bos WJ, (2012) Treatment with anti-inflammatory drugs in community-acquired pneumonia. J Intern 272: 25–35 [Google Scholar]
  • Tsai HY, Liao CH, Liu CY, Huang YT, Hsueh PR, (2015) In vitro synergy of penicillin, ceftriaxone and levofloxacin against serotype 19A Streptococcus pneumoniae. Int J Antimicrob Agents 46: 722–725 [CrossRef] [PubMed] [Google Scholar]
  • Dalhoff A, Shalit I, (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3: 359–371 [CrossRef] [PubMed] [Google Scholar]
  • Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup, (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39: 165–228 [CrossRef] [PubMed] [Google Scholar]
  • Aspa J, Rajas O, Rodriguez de Castro F, Huertas MC, Borderías L, Cabello FJ, Tábara J, Hernández-Flix S, Martinez-Sanchis A, Torres A; Pneumococcal Pneumonia in Spain Study Group, (2006) Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27: 1010–1019 [PubMed] [Google Scholar]
  • De Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators, (2002) Dexamethasone in adults with bacterial meningitis. N Engl J Med 347: 1549–1556 [CrossRef] [PubMed] [Google Scholar]
  • Nie W, Zhang Y, Cheng J, Xiu Q, (2012) Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLos One 7:e47926 [PubMed] [Google Scholar]
  • Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, Vandvik PO, Loeb M, Guyatt GH, (2015) Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 163: 519–528 [CrossRef] [PubMed] [Google Scholar]
  • Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M, (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385: 1511–1518 [CrossRef] [PubMed] [Google Scholar]
  • Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN, (1993) Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med 94: 153–159 [CrossRef] [PubMed] [Google Scholar]
  • Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, Gabarrús A, Sellarés J, Restrepo MI, Anzueto A, Niederman MS, Agustí C, (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313: 677–686 [CrossRef] [PubMed] [Google Scholar]
  • Werno AM, Murdoch DR, (2008) Medical microbiology: laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis 46: 926–932 [CrossRef] [PubMed] [Google Scholar]
  • Moïsi JC, Saha SK, Falade AG, Njanpop-Lafourcade BM, Oundo J, Zaidi AK, Afroj S, Bakare RA, Buss JK, Lasi R, Mueller J, Odekanmi AA, Sangaré L, Scott JA, Knoll MD, Levine OS, Gessner BD, (2009) Enhanced diagnosis of pneumococcal meningitis with use of the Binax NOW immunochromatographic test of Streptococcus pneumoniae antigen: a multisite study. Clin Infect Dis 48: S49–S56 [CrossRef] [PubMed] [Google Scholar]
  • Parent du Châtelet I, Traore Y, Gessner BD, Antignac A, Naccro B, Njanpop-Lafourcade BM, Ouedraogo MS, Tiendrebeogo SR, Varon E, Taha MK, (2005) Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing. Clin Infect Dis 40: 17–25 [CrossRef] [PubMed] [Google Scholar]
  • Viasus D, Simonetti AF, Garcia-Vidal C, Niubó J, Dorca J, Carratalà J, (2016) Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. J Antimicrob Chemother pii: dkw441 [Epub ahead of print] [PubMed] [Google Scholar]
  • Tateda K, Kusano E, Matsumoto T, Kimura K, Uchida K, Nakata K, Yamaguchi K, (2006) Semi-quantitative analysis of Streptococcus pneumoniae urinary antigen: kinetics of antigen titers and severity of diseases. Scand J Infect Dis 38: 166–171 [CrossRef] [PubMed] [Google Scholar]
  • Cvitkovic Spik V, Beovic B, Pokorn M, Drole Torkar A, Vidmar D, Papst L, Seme K, Kogoj R, Müller Premru M, (2013) Improvement of pneumococcal pneumonia diagnostics by the use of rt-PCR on plasma and respiratory samples. Scand J Infect Dis 45: 731–737 [CrossRef] [PubMed] [Google Scholar]
  • Rello J, Lisboa T, Lujan M, Gallego M, Kee C, Kay I, Lopez D, Waterer GW; DNA-Neumococo Study Group, (2009) Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest 136: 832–840 [PubMed] [Google Scholar]
  • Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH, (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 90: 223–229 [CrossRef] [PubMed] [Google Scholar]
  • Gaieski DF, Edwards JM, Kallan MJ, Carr BG, (2013) Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41: 1167–1174 [CrossRef] [PubMed] [Google Scholar]
  • Bijlsma MW, Brouwer MC, Kasanmoentalib ES, Kloek AT, Lucas MJ, Tanck MW, van der Ende A, van de Beek D, (2016) Community-acquired bacterial meningitis in adults in the Netherlands, 2006–2014: a prospective cohort study. Lancet Infect Dis 16: 339–347 [CrossRef] [PubMed] [Google Scholar]
  • Buchholz G, Koedel U, Pfister HW, Kastenbauer S, Klein M, (2016) Dramatic reduction of mortality in pneumococcal meningitis. Crit Care 20: 312 [CrossRef] [PubMed] [Google Scholar]
  • Amaro R, Liapikou A, Cilloniz C, Gabarrus A, Marco F, Sellares J, Polverino E, Garau J, Ferrer M, Musher DM, Torres A, (2016) Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia. Eur Respir J 48: 797–807 [PubMed] [Google Scholar]
  • Mongardon N, Max A, Bouglé A, Pène F, Lemiale V, Charpentier J, Cariou A, Chiche JD, Bedos JP, Mira JP, (2012) Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care 16: R155 [CrossRef] [PubMed] [Google Scholar]
  • Gattarello S, Borgatta B, Solé-Violán J, Vallés J, Vidaur L, Zaragoza R, Torres A, Rello J; Community-acquired Pneumonia en la Unidad de Cuidados Intensivos II Study Investigators, (2014) Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013). Chest 146: 22–31 [PubMed] [Google Scholar]
  • Ricketson LJ, Nettel-Aguirre A, Vanderkooi OG, Laupland KB, Kellner JD, (2013) Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study. PLoS One 8: e71924 [PubMed] [Google Scholar]
  • Vernater J, Pirofski L, (2013) Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis 26: 277–283 [PubMed] [Google Scholar]
  • Burgos J, Luján M, Larrosa MN, Fontanals D, Bermudo G, Planes AM, Puig M, Rello J, Falcó V, Pahissa A, (2014) Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. Eur Respir J 43: 545–553 [PubMed] [Google Scholar]
  • Naucler P, Darenberg J, Morfeldt E, Ortqvist A, Henriques Normark B, (2013) Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 68: 571–579 [CrossRef] [PubMed] [Google Scholar]
  • Corrales-Medina VF, Musher DM, Wells GA, Wells GA, Chirinos JA, Chen L, Fine MJ, (2012) Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 125: 773–781 [CrossRef] [PubMed] [Google Scholar]
  • Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, Newman A, Loehr L, Folsom AR, Elkind MS, Lyles MF, Kronmal RA, Yende S, (2015) Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 313: 264–274 [CrossRef] [PubMed] [Google Scholar]
  • Corrales-Medina VF, Taljaard M, Yende S, Kronmal R, Dwivedi G, Newman AB, Elkind MS, Lyles MF, Chirinos JA, (2015) Intermediate and long-term risk of new-onset heart failure after hospitalization for pneumonia in elderly adults. Am Heart J 170: 306–312 [CrossRef] [PubMed] [Google Scholar]
  • Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P, (2012) Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122: 23–35 [CrossRef] [PubMed] [Google Scholar]
  • Brown AO, Mann B, Gao G, Hankins JS, Humann J, Giardina J, Faverio P, Restrepo MI, Halade GV, Mortensen EM, Lindsey ML, Hanes M, Happel KI, Nelson S, Bagby GJ, Lorent JA, Cardinal P, Granados R, Esteban A, LeSaux CJ, Tuomanen EI, Orihuela CJ, (2014) Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 10: e1004383 [PubMed] [Google Scholar]
  • Alhamdi Y, Neill DR, Abrams ST, Malak HA, Yahya R, Barrett-Jolley R, Wang G, Kadioglu A, Toh CH, (2015) Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection. PLoS Pathog 11: e1004836 [PubMed] [Google Scholar]
  • Nel JG, Durandt C, Mitchell TJ, Feldman C, Anderson R, Tintinger GR, (2016) Pneumolysin mediates platelet activation in vitro. Lung 194: 589–593 [CrossRef] [PubMed] [Google Scholar]
  • Brown AO, Millett ER, Quint JK, Orihuela CJ, (2015) Cardiotoxicity during invasive pneumococcal disease. Am J Respir Crit Care Med 191: 739–745 [CrossRef] [PubMed] [Google Scholar]
  • Rosch JW, Boyd AR, Hinojosa E, Pestina T, Hu Y, Persons DA, Orihuela CJ, Tuomanen EI, (2010) Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest 120: 627–635 [PubMed] [Google Scholar]
  • Havers F, Bramley AM, Finelli L, Reed C, Self WH, Trabue C, Fakhran S, Balk R, Courtney DM, Girard TD, Anderson EJ, Grijalva CG, Edwards KM, Wunderink RG, Jain S, (2016) Statin use and hospital length of stay among adults hospitalized with community-acquired Pneumonia. Clin Infect Dis 62: 1471–1478 [CrossRef] [PubMed] [Google Scholar]
  • Tsai CJ, Griffin MR, Nuorti JP, Grijalva CG, (2008) Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis 46: 1664–1672 [CrossRef] [PubMed] [Google Scholar]
  • Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR, (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369: 1179–1186 [CrossRef] [PubMed] [Google Scholar]
  • Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG, (2013) U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 369: 155–163 [CrossRef] [PubMed] [Google Scholar]
  • http://social-sante.gouv.fr/IMG/pdf/calendrier_vaccinal_2016.pdf, p 22 [Google Scholar]
  • Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG, (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 196: 1346–1354 [CrossRef] [PubMed] [Google Scholar]
  • Ricketson LJ, Vanderkooi OG, Wood ML, Leal J, Kellner JD, (2014) Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta. Can J Infect Dis Med Microbiol 25: e71–e75 [PubMed] [Google Scholar]
  • Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE, (2015) Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372: 1114–1125 [CrossRef] [PubMed] [Google Scholar]
  • Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B, (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174: 84–93 [CrossRef] [PubMed] [Google Scholar]
  • Kristoffersen KB, Søgaard OS, Wejse C, Black FT, Greve T, Tarp B, Storgaard M, Sodemann M, (2009) Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission — a randomized trial. Clin Microbiol Infect 15: 481–487 [PubMed] [Google Scholar]
  • Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B; ProHOSP Study Group, (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302: 1059–1066 [CrossRef] [PubMed] [Google Scholar]
  • De Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW, (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16: 819–827 [CrossRef] [PubMed] [Google Scholar]
  • Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, Schouten JA, Degener JE, Janknegt R, Verheij TJ, Sachs AP, Prins JM; Dutch Working Party on Antibiotic Policy; Dutch Association of Chest Physicians, (2012) SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med 70: 90–101 [PubMed] [Google Scholar]
  • BTS guidelines 2015 https://www.brit-thoracic.org.uk/guidelines-and-qualitystandards/community-acquired-pneumonia-in-adults-guideline/annotated-bts-guideline-for-the-management-of-cap-in-adults 2014/ [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.